Nationwide	O
,	O
Multicenter	B:C1096776
,	O
Retrospective	O
Study	I:C0035363
on	O
High	O
-	I:C0454270
Dose	I:C0454270
-	I:C0454270
Rate	I:C0454270
Brachytherapy	I:C0454270
as	O
Monotherapy	O
for	O
Prostate	O
Cancer	I:C0376358
.	O

Nationwide	O
,	O
Multicenter	O
,	O
Retrospective	B:C0035363
Study	I:C0035363
on	O
High	O
-	I:C0454270
Dose	I:C0454270
-	I:C0454270
Rate	I:C0454270
Brachytherapy	I:C0454270
as	O
Monotherapy	O
for	O
Prostate	O
Cancer	I:C0376358
.	O

Nationwide	O
,	O
Multicenter	O
,	O
Retrospective	O
Study	I:C0035363
on	O
High	B:C0454270
-	I:C0454270
Dose	I:C0454270
-	I:C0454270
Rate	I:C0454270
Brachytherapy	I:C0454270
as	O
Monotherapy	O
for	O
Prostate	O
Cancer	I:C0376358
.	O

Nationwide	O
,	O
Multicenter	O
,	O
Retrospective	O
Study	I:C0035363
on	O
High	O
-	I:C0454270
Dose	I:C0454270
-	I:C0454270
Rate	I:C0454270
Brachytherapy	I:C0454270
as	O
Monotherapy	B:C0087111
for	O
Prostate	O
Cancer	I:C0376358
.	O

Nationwide	O
,	O
Multicenter	O
,	O
Retrospective	O
Study	I:C0035363
on	O
High	O
-	I:C0454270
Dose	I:C0454270
-	I:C0454270
Rate	I:C0454270
Brachytherapy	I:C0454270
as	O
Monotherapy	O
for	O
Prostate	B:C0376358
Cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	B:C1096776
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	B:C0035363
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	B:C0454270
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	B:C0454270
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	B:C0087111
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	B:C3640764
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

To	O
present	O
,	O
analyze	O
,	O
and	O
discuss	O
results	O
of	O
a	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
on	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
(	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
)	O
as	O
monotherapy	O
for	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	B:C0376358
cancer	I:C0376358
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	B:C3640764
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
at	O
5	O
institutions	O
in	O
Japan	O
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	O
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
at	O
5	O
institutions	O
in	O
Japan	O
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	O
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	B:C0376358
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
at	O
5	O
institutions	O
in	O
Japan	O
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	O
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	B:C0454270
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
at	O
5	O
institutions	O
in	O
Japan	O
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	O
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	B:C0087111
at	O
5	O
institutions	O
in	O
Japan	O
.	O

From	O
1995	O
through	O
2013	O
,	O
524	O
patients	O
,	O
73	O
(	O
14	O
%	O
)	O
with	O
low	O
-	O
risk	O
,	O
207	O
(	O
40	O
%	O
)	O
with	O
intermediate	O
-	I:C3640764
risk	I:C3640764
,	O
and	O
244	O
(	O
47	O
%	O
)	O
with	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
,	O
were	O
treated	O
with	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
at	O
5	O
institutions	O
in	O
Japan	B:C0022341
.	O

Dose	B:C0524811
fractionations	I:C0524811
were	O
27	O
Gy	O
/	O
2	O
fractions	O
for	O
69	O
patients	O
(	O
13	O
%	O
)	O
,	O
45.5	O
Gy	O
/	O
7	O
fractions	O
for	O
168	O
(	O
32	O
%	O
)	O
,	O
49	O
Gy	O
/	O
7	O
fractions	O
for	O
149	O
(	O
28	O
%	O
)	O
,	O
54	O
Gy	O
/	O
9	O
fractions	O
for	O
130	O
(	O
25	O
%	O
)	O
,	O
and	O
others	O
for	O
8	O
(	O
2	O
%	O
)	O
.	O

Of	O
these	O
patients	O
,	O
156	O
(	O
30	O
%	O
)	O
did	O
not	O
receive	O
androgen	B:C0279492
deprivation	I:C0279492
therapy	I:C0279492
,	O
and	O
202	O
patients	O
(	O
39	O
%	O
)	O
did	O
receive	O
androgen	O
deprivation	I:C0279492
therapy	I:C0279492
<	O
1	O
year	O
,	O
112	O
(	O
21	O
%	O
)	O
for	O
1	O
-	O
3	O
years	O
,	O
and	O
54	O
(	O
10	O
%	O
)	O
for	O
>	O
3	O
years	O
.	O

Of	O
these	O
patients	O
,	O
156	O
(	O
30	O
%	O
)	O
did	O
not	O
receive	O
androgen	O
deprivation	I:C0279492
therapy	I:C0279492
,	O
and	O
202	O
patients	O
(	O
39	O
%	O
)	O
did	O
receive	O
androgen	B:C0279492
deprivation	I:C0279492
therapy	I:C0279492
<	O
1	O
year	O
,	O
112	O
(	O
21	O
%	O
)	O
for	O
1	O
-	O
3	O
years	O
,	O
and	O
54	O
(	O
10	O
%	O
)	O
for	O
>	O
3	O
years	O
.	O

Median	B:C1522577
follow	I:C1522577
-	I:C1522577
up	I:C1522577
time	O
was	O
5.9	O
years	O
(	O
range	O
,	O
0.4	O
-	O
18.1	O
years	O
)	O
,	O
with	O
a	O
minimum	O
of	O
2	O
years	O
for	O
surviving	O
patients	O
.	O

After	O
5	O
years	O
,	O
respective	O
actuarial	O
rates	O
of	O
no	B:C1513916
biochemical	O
evidence	O
of	O
disease	O
,	O
overall	O
survival	O
,	O
cause	O
-	O
specific	O
survival	O
,	O
and	O
metastasis	O
-	O
free	O
survival	O
for	O
all	O
patients	O
were	O
92	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
,	O
and	O
94	O
%	O
.	O

After	O
5	O
years	O
,	O
respective	O
actuarial	O
rates	O
of	O
no	O
biochemical	O
evidence	O
of	O
disease	B:C0012634
,	O
overall	O
survival	O
,	O
cause	O
-	O
specific	O
survival	O
,	O
and	O
metastasis	O
-	O
free	O
survival	O
for	O
all	O
patients	O
were	O
92	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
,	O
and	O
94	O
%	O
.	O

After	O
5	O
years	O
,	O
respective	O
actuarial	O
rates	O
of	O
no	O
biochemical	O
evidence	O
of	O
disease	O
,	O
overall	O
survival	O
,	O
cause	O
-	O
specific	O
survival	O
,	O
and	O
metastasis	B:C4255448
-	O
free	O
survival	O
for	O
all	O
patients	O
were	O
92	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
,	O
and	O
94	O
%	O
.	O

For	O
low	O
/	O
intermediate	B:C3640764
/	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
,	O
the	O
5	O
-	O
year	O
no	O
biochemical	O
evidence	O
of	O
disease	O
rates	O
were	O
95%/94%/89	O
%	O
,	O
the	O
5	O
-	O
year	O
overall	O
survival	O
rates	O
were	O
98%/98%/94	O
%	O
,	O
the	O
5	O
-	O
year	O
cause	O
-	O
specific	O
survival	O
rates	O
were	O
98%/100%/98	O
%	O
,	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
-	O
free	O
survival	O
rates	O
were	O
98%/95%/90	O
%	O
,	O
respectively	O
.	O

For	O
low	O
/	O
intermediate	O
/	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
patients	O
,	O
the	O
5	O
-	O
year	O
no	O
biochemical	O
evidence	O
of	O
disease	O
rates	O
were	O
95%/94%/89	O
%	O
,	O
the	O
5	O
-	O
year	O
overall	O
survival	O
rates	O
were	O
98%/98%/94	O
%	O
,	O
the	O
5	O
-	O
year	O
cause	O
-	O
specific	O
survival	O
rates	O
were	O
98%/100%/98	O
%	O
,	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
-	O
free	O
survival	O
rates	O
were	O
98%/95%/90	O
%	O
,	O
respectively	O
.	O

For	O
low	O
/	O
intermediate	O
/	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
,	O
the	O
5	O
-	O
year	O
no	B:C1513916
biochemical	O
evidence	O
of	O
disease	O
rates	O
were	O
95%/94%/89	O
%	O
,	O
the	O
5	O
-	O
year	O
overall	O
survival	O
rates	O
were	O
98%/98%/94	O
%	O
,	O
the	O
5	O
-	O
year	O
cause	O
-	O
specific	O
survival	O
rates	O
were	O
98%/100%/98	O
%	O
,	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
-	O
free	O
survival	O
rates	O
were	O
98%/95%/90	O
%	O
,	O
respectively	O
.	O

For	O
low	O
/	O
intermediate	O
/	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
,	O
the	O
5	O
-	O
year	O
no	O
biochemical	O
evidence	O
of	O
disease	O
rates	O
were	O
95%/94%/89	O
%	O
,	O
the	O
5	O
-	O
year	O
overall	O
survival	O
rates	O
were	O
98%/98%/94	O
%	O
,	O
the	O
5	O
-	O
year	O
cause	O
-	O
specific	O
survival	O
rates	O
were	O
98%/100%/98	O
%	O
,	O
and	O
the	O
5	O
-	O
year	O
metastasis	B:C4255448
-	O
free	O
survival	O
rates	O
were	O
98%/95%/90	O
%	O
,	O
respectively	O
.	O

The	O
cumulative	O
incidence	O
of	O
late	O
grade	B:C0441800
2	O
to	O
3	O
genitourinary	O
toxicity	O
at	O
5	O
years	O
was	O
19	O
%	O
,	O
and	O
that	O
of	O
late	O
grade	O
3	O
was	O
1	O
%	O
.	O

The	O
cumulative	O
incidence	O
of	O
late	O
grade	O
2	O
to	O
3	O
genitourinary	B:C3887515
toxicity	O
at	O
5	O
years	O
was	O
19	O
%	O
,	O
and	O
that	O
of	O
late	O
grade	O
3	O
was	O
1	O
%	O
.	O

The	O
cumulative	O
incidence	O
of	O
late	O
grade	O
2	O
to	O
3	O
genitourinary	O
toxicity	B:C0600688
at	O
5	O
years	O
was	O
19	O
%	O
,	O
and	O
that	O
of	O
late	O
grade	O
3	O
was	O
1	O
%	O
.	O

The	O
cumulative	O
incidence	O
of	O
late	O
grade	O
2	O
to	O
3	O
genitourinary	O
toxicity	O
at	O
5	O
years	O
was	O
19	O
%	O
,	O
and	O
that	O
of	O
late	O
grade	B:C0441800
3	O
was	O
1	O
%	O
.	O

The	O
corresponding	O
incidences	O
of	O
gastrointestinal	B:C0521362
toxicity	O
were	O
3	O
%	O
and	O
0	O
%	O
(	O
0.2	O
%	O
)	O
.	O

The	O
corresponding	O
incidences	O
of	O
gastrointestinal	O
toxicity	B:C0600688
were	O
3	O
%	O
and	O
0	O
%	O
(	O
0.2	O
%	O
)	O
.	O

No	B:C1513916
grade	O
4	O
or	O
5	O
of	O
either	O
type	O
of	O
toxicity	O
was	O
detected	O
.	O

No	O
grade	B:C0441800
4	O
or	O
5	O
of	O
either	O
type	O
of	O
toxicity	O
was	O
detected	O
.	O

No	O
grade	O
4	O
or	O
5	O
of	O
either	O
type	O
of	O
toxicity	B:C0600688
was	O
detected	O
.	O

No	O
grade	O
4	O
or	O
5	O
of	O
either	O
type	O
of	O
toxicity	O
was	O
detected	B:C0442726
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	B:C1096776
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	B:C0035363
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	B:C0454270
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	B:C0087111
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	B:C3640764
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
prostate	O
cancer	I:C0376358
.	O

The	O
findings	O
of	O
this	O
nationwide	O
,	O
multicenter	O
,	O
retrospective	O
study	I:C0035363
demonstrate	O
that	O
high	O
-	I:C0454270
dose	I:C0454270
-	I:C0454270
rate	I:C0454270
brachytherapy	I:C0454270
as	O
monotherapy	O
was	O
safe	O
and	O
effective	O
for	O
all	O
patients	O
with	O
low	O
-	O
,	O
intermediate	O
-	I:C3640764
,	O
and	O
high	O
-	I:C0332167
risk	I:C0332167
prostate	B:C0376358
cancer	I:C0376358
.	O

